Chronic myelogenous leukemia: From molecular biology to clinical aspects and novel targeted therapies

Journal of Nippon Medical School

Volumn 73, Issue 4, 2006, Pages 178-192

  Inokuchi, Koiti ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Chronic myelogenous leukemia; Imatinib; Transgenic mice

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE;

CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DRUG BINDING SITE; DRUG POTENCY; DRUG RESISTANCE; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; MOLECULAR BIOLOGY; NONHUMAN; ONCOGENE; PHENOTYPE; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; DISEASE MODELS, ANIMAL; GENES, ABL; LEUKEMIA, MYELOID, CHRONIC; MICE; MICE, TRANSGENIC; PIPERAZINES; PYRIMIDINES;

EID: 33747694441     PISSN: 13454676     EISSN: 13473409     Source Type: Journal    
DOI: 10.1272/jnms.73.178     Document Type: Review

References (89)

1. Bennett JH: Case of hypertrophy of the spleen and liver, in which death took place from suppuration of the blood. Edinburgh Medical and Surgical Journal 1845; 64: 413-423.
2. Cragie D: Case of disease of the spleen, in which death took place in consequence of the presence of purulent matter in the blood. Edinburgh Medical and Surgical Journal 1845; 64: 400-413.
3. Virchow R: Weisses Blut. Froriep's Notizen 1845; 36: 151-156.
4. Neumann E: Uber myelogene leukemia. Berliner Klinische Wochenschreibe 1878; 15: 69-72.
5. Nowell PC, Hungerford DAA: minute chromosome in human chrnic granulocytic leukemia. Science 1960; 132: 1497.
6. Rowley JD: A new consistent chromosomal abnormality in chrnic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290-293.
7. Groffen J, Stephenson JR, Heinterkamp N, De Klein A, Bartram CR, Grosveld G: Philaderphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984; 36: 93-99.
8. Shtivelman E, Lifshitz B, Gale RP, Canaani E: Fused transcript of abl and bcr genes in chrnic myelogenous leukemia. Nature 1985; 315: 550-554.
9. bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824-830.
10. Zhang X, Rong R, Hao SX, Pear WS, Ren R: The SH2 domain of Bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype. Blood 2001; 97: 277-287.
11. Ghaffari S, Daley GQ, Lodish HF: Growth factor independence and BCR/ABL transformation: promise and pitfalls of murine model systems and assays. Leukemia 1999; 13: 1200-1206.
12. Pendergast AM, Muller AJ, Havlik MH, Maru Y, Witte ON: BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell 1991; 66: 161-171.
13. dok a constitutively tyrosine-phosphorylated , GAP-associated protein in chronic myelogenous leukemia progenitor cells. Cell 1997; 88: 197-204.
14. Bhat A, Kolibaba K, Oda T, Ohno-Jones S, Heaney C, Druker BJ: Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed myeloid cells. J Biol Chem 1997; 272: 16170-16175.
15. Roumiantsev S, de Aos IE, Varticovski L, Ilaria R, Van Etten RA: The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase. Blood 2001; 97: 4-13.
16. Kip, which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity. Proc Natl Acad Sci USA 2000; 97: 10538-10543.
17. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ: Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 1994; 83: 2038-2044.
18. Jahagirdar BN, Miller JS, Shet A, Verfaillie CM: Novel therapies for chronic myelogenous leukemia. Exp Hematol 2001; 29: 543-556.
19. Gishizky ML, Witte ON: Initiation of dysregulated growth of multipotent progenitor cells by bcr-abl in vitro. Science 1992; 256: 836-839.
20. Sawyers CL: Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330-1340.
21. Cortez D, Reuther G, Pendergast AM: The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates Gl-to-S phase transition in hematopoietic cells. Oncogene 1997; 15: 2333-2342.
22. Pendergast AM, Quilliam LA, Cripe LD, et al.: BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 1993; 75: 175-185.
23. Skorski T, Bellacosa A, Nieborowska-Skorska M, et al.: Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 1997; 16: 6151-6161.
24. Hariharan IK, Harris AW, Crawford M, et al.: A bcr-v-abl oncogene induces lymphomas in transgenic mice. Molecular Cell Biology 1989; 9: 2798-2805.
25. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Goffen J: Acute leukaemia in bcr/abl transgenic mice. Nature 1990; 344: 251-253.
26. Pear WS, Miller JP, Xu L, et al.: Efficient and Rapid Induction of a Chronic Myelogenous Leukemia-Like Myeloproliferative Disease in Mice Receiving P210 bcr/abl-Transduced Bone Marrow. Blood 1998; 92: 3780-3792.
27. Zhang X, Ren R: Bcr-Abl Efficiently Induces a Myeloproliferative Disease and Production of Excess Interleukin-3 and Granulocyte-Macrophage Colony-Stimulating Factor in Mice: A Novel Model for Chronic Myelogenous Leukemia. Blood 1998; 92: 3829-3840.
28. Li S, Ilaria RJ, Million RP, Daley GQ, Van Etten RA: The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 1999; 189: 1399-1412.
29. Dick JE: Normal and leukemic human stem cells assayed in SCID mice. Semin Immunol 1996; 8: 197-206.
30. Pflumio F, Izac B, Katz A, Shultz LD, Vainchenker W, Coulombel L: Phenotype and function of human hematopoietic cells engrafting immune- deficient CB 17-severe combined immunodeficiency mice and nonobese diabetic-severe combined immunodeficiency mice after transplantation of human cord blood mononuclear cells. Blood 1996; 88: 3731-3740.
31. Cashman JD, Lapidot T, Wang JCY, et al.: Kinetic Evidence of the Regeneration of Multilineage Hematopoiesis From Primitive Cells in Normal Human Bone Marrow Transplanted Into Immunodeficient Mice. Blood 1997; 89: 4307-4316.
32. Sirard C, Lapidot T, Vormoor J, et al.: Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis. Blood 1996; 87: 1539-1548.
33. Dazzi F, Capelli D, Hesserjian R, et al.: The Kinetics and Extent of Engraftment of Chronic Myelogenous Leukemia Cells in Non-Obese Diabetic/Severe Combined Immunodeficiency Mice Reflect the Phase of the Donor's Disease: An In vivo Model of Chronic Myelogenous Leukemia Biology. Blood 1998; 92: 1390-1396.
34. + Cells. Blood 1988; 91: 630-640.
35. Van Etten RA: Models of chronic myeloid leukemia. Curr Oncol Rep 2001; 3: 228-237.
36. Heisterkamp N, Jenster G, Kioussis D, Pattengale PK, Goffen J: Human bcr-abl gene has a lethal effect on embryogenesis. Transgenic Res 1991; 1: 45-53.
37. 1-Positive Leukemias. Blood 1998; 91: 2067-2075.
38. Inokuchi K, Dan K, Takatori M, et al.: Myeloproliferative disease in transgenic mice expressing P230 Bcr/Abl: longer disease latency, thrombocytosis, and mild leukocytosis. Blood 2003; 102: 320-322.
39. Huettner CS, Zhang P, Van Etten RA, Tenen DG: Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 2000; 24: 57-60.
40. Huettner CS, Koschmieder S, Iwasaki H, et al.: Inducible expression of BCR/ABL using human CD 34 regulatory elements results in a megakaryocytic myeloproliferative syndrome. Blood 2003; 102: 3363-3370.
41. Koschmieder S, Gottgens B, Zhang P, et al.: Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood 2005; 105: 324-334.
42. Verstovsek S, Lin H, Kantarjian H, et al.: Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course. Cancer 2002; 94: 2416-2425.
43. Yamagata T, Mitani K, Kanda Y, Yazaki Y, Hirai H: Elevated platelet count features the variant type of BCR/ABL junction in chronic myelogenous leukaemia. Br J Haematol 1996; 94: 370-372.
44. Roumiantsev S, de Aos I, Varticovski L, Ilaria RL, Van Etten RA: The Src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase. Blood 2001; 97: 4-13.
45. Advani AS, Pendergast AM: Bcb-Abl variants: biological and clinical aspects. Leukem Res 2002; 26: 713-720.
46. Wada H, Mizutani S, Nishimura J, et al.: Establishment and molecular characterization of a novel leukemic cell line with Philadelphia chromosome expressing p230 BCR/ABL fusion protein. Cancer Res 1995; 55: 3192-3196.
47. Diekmann D, Brill S, Garrett MD, et al.: Bcr encodes a GTPase-activating protein for p21rac. Nature 1991; 351: 400-402.
48. Laneuville P: Abl tyrosine protein kinase. Semin Immunol 1995; 7: 255-266.
49. Hu Y, Liu Y, Pelletier S, et al.: Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004; 36: 453-461.
50. Melo JV: The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996; 88: 2375-2384.
51. Kurzrock R, Shtalrid M, Romero P, et al.: A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukemia. Nature 1987; 325: 631-635.
52. Chan L, Karhi KK, Rayter SI, et al.: A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukemia. Nature 1987; 325: 635-637.
53. Quackenbush RQ, Reuther GW, Miller JP, Courtney KD, Pear WS, Pendergast AM: Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases. Blood 2000; 95: 2913-2921.
54. Pane F, Friger F, Sindona M, et al.: Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker BCR/ABL with C3/A2 junction. Blood 1996; 88: 2410-2414.
55. McLaughlin J, Chianese E, Witte ON: Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells. Mol Cell Biol 1989; 9: 1866-1874.
56. Lugo TG, Pendergast AM, Muller AJ, Witte ON: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247: 1079-1082.
57. Okuda K, Golub TR, Gilliland DG, Griffin JD: p210 BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. Oncogene 1996; 13: 1147-1152.
58. Didsbury J, Weber RF, Bokoch GM, Evans T, Snyderman R: Rac, a novel ras-related family of proteins that are botulinum toxin substrates. J Biol Chem 1989; 264: 16378-16382.
59. McWhirter JR, Wang JY: Effect of Bcr sequences on the cellular function of the Bcr-Abl oncoprotein. Oncogene 1997; 15: 1625-1634.
60. Ridley AJ, Hall A: The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 1992; 70: 389-399.
61. Mills KI, Anderson VA, Burns JH, Birnie GD: The site of the breakpoint within the bcr is a prognostic factor in Philadelphia-positive CML patients. Blood 1988; 72: 1237-1241.
62. Fioretos T, Nilsson PG, Aman P, et al.: Clinical impact of breakpoint position within M-bcr in chronic myeloid leukemia. Leukemia 1993; 7: 1225-1231.
63. Shepherd P, Suffolk R, Halsey J, Allan N: Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival. Br J Haematol 1995; 89: 546-554.
64. Inokuchi K, Inoue T, Tojo A, et al.: A possible correlation between the type of bcr-abl hybrid messenger RNA and platelet count in Philadelphia-positive chronic myelogenous leukemia. Blood 1991; 78: 3125-3127.
65. Inokuchi K, Futaki M, Yamada T, et al.: The relationship between the site of breakpoints within the bcr gene and thrombopoiesis of Philadelphia-positive chronic myelocytic leukemia. Leukemia Research 1991; 15: 1067-1073.
66. Perego RA, Costantini M, Cornacchini G, et al.: The possible influences of B2A2 and B3A2 BCR/ABL protein structure on thrombopoiesis in chronic myeloid leukaemia. Eur J Cancer 2000; 36: 1395-1401.
67. Martinez-Mancilla M, Gutierrez M, Zafra de la Rosa G, Garcia-Carranca A, Gariglio P, Miranda E: Younger age and shorter chronic phase in b2a2-positive chronic myeloid leukemia adults with high white blood cell count at diagnosis. Haematologica 2002; 87: 666-668.
68. Zaccaria A, Martinelli G, Buzzi M, Farabegoli P: Will molecular biology contribute to refine prognosis and to select treatment? The Molecular Biology Committee. Italian Cooperative Study Group on Chronic Myeloid Leukemia. Leuk Lymphoma 1993; 11, Suppl 1: 81-89.
69. Cervantes F, Colomer D, Vives-Corrons JL, Rozman C, Montserrat E: Chronic myeloid leukemia of thrombocythemic onset: a CML subtype with distinct hematological and molecular features? Leukemia 1996; 10: 1241-1243.
70. Blickstein D, Aviram A, Luboshitz J, et al.: BCR-ABL transcripts in bone marrow aspirates of Philadelphia-negative essential thrombocytopenia patients: clinical presentation. Blood 1997; 90: 2768-2771.
71. Verstovsek S, Lin H, Kantarjian H, et al.: Neutrophilic-chronic myeloid leukemia: Low levels of p230 BCR/ABL mRNA and undetectable p230 BCR/ABL protein may predict an indolent course. Cancer 2002; 94: 2416-2425.
72. Pane F, Intrieri M, Quintarelli C, Izzo B, Muccioli GC, Salvatore F: BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations. Oncogene 2002; 21: 8652-8667.
73. Druker BJ, Tamura S, Buchdunger E, et al.: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-566.
74. Buchdunger E, Zimmermann J, Mett H, et al.: Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56: 100-104.
75. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J: Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000; 289: 1938-1942.
76. Druker BJ, Talpaz M, Resta DJ, et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
77. Cohen MH, Williams G, Johnson JR, et al.: Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002; 8: 935-942.
78. Gorre ME, Mohammed M, Ellwood K, et al.: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-880.
79. Branford S, Rudzki Z, Walsh S, et al.: High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI 571) resistance. Blood 2002; 99: 3472-3475.
80. Le Coutre P, Tassi E, Varella-Garcia M, et al.: Induction of resistance to the Abelson inhibitor STI 571 in human leukemic cells through gene amplification. Blood 2000; 95: 1758-1766.
81. Hochhaus A, Kreil S, Corbin AS, et al.: Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190-2196.
82. Schindler T, Bornmann W, Pellicena P, Miller WT, B. Clarkson B, Kuriyan J: Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000; 289: 1938-1942.
83. Weisberg E, Manley PW, Breitenstein W, et al.: Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129-141.
84. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399-401.
85. Gumireddy K, Baker SJ, Cosenza SC, et al.: A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci USA 2005; 102: 1992-1997.
86. Tefferi A, Bren GD, Wagner KV, Schaid DJ, Ash RC, Thinbodeau SN: The location of the Philadelphia chromosomal breakpoint site and prognosis in chronic granulocytic leukemia. Leukemia 1990; 4: 839-842.
87. Shepherd PCA, Bond C, Allan NC: Molecular breakpoints and platelet counts in chrnic myeloid leukemia. Blood 1992; 80: 556-557.
88. Inokuchi K: Transgenic mouse models of BCR/ABL-positive chronic myelogenous leukemia: A Review. Curr Genom 2005; 6: 89-95.
89. Inokuchi K, Nomura T: The relationship between the type of bcr-abl hybrid messenger RNA and thrombopoiesis in Philadelphia-positive chrnic myelogenous leukemia. Leukem Lymphom 1993; 10: 9-15.